Atlas Trials

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

Clinical trial NCT05664893 · WITHDRAWN

Trial details

NCT number
NCT05664893
Sponsor
Centre Antoine Lacassagne
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HER2 Negative Breast Cancer Not Immediately Operated
Start date
2023-06-26
Primary completion
2026-03-26
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.